Showing results (31-40 of 54) with videos related to
Sort By:
Pageof 6
Journal for Immunotherapy of Cancer|May 31, 2024
Nivolumab plus relatlimab in patients with previously treated microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 studyMichael J Overman, Fabio Gelsomino, Massimo Aglietta, et al.Advances in Therapy|November 18, 2025
Tislelizumab + Chemotherapy in Gastric Cancer: Long-Term RATIONALE-305 Randomized Trial Follow-upMarcia Cruz-Correa, Do-Youn Oh, Ken Kato, et al.Investigational New Drugs|June 22, 2026
Evaluating pegenzileukin (SAR444245/THOR-707) in combination with pembrolizumab or cetuximab in advanced metastatic gastrointestinal cancer: the PEGATHOR phase 2 studyWilliam P Harris, Pilar García-Alfonso, Jean Phillipe Metges, et al.Investigational New Drugs|February 12, 2017
Phase II study of the antibody-drug conjugate TAK-264 (MLN0264) in patients with metastatic or recurrent adenocarcinoma of the stomach or gastroesophageal junction expressing guanylyl cyclase CKhaldoun Almhanna, Maria Luisa Limon Miron, David Wright, et al.Journal of Gastrointestinal Oncology|May 19, 2025
Circulating tumor DNA using a plasma-only assay predicts survival in patients with oligometastatic colorectal cancer after definitive therapyEnrique Sanz-Garcia, Paloma Peinado, Adrián Peláez, et al.Investigational New Drugs|May 21, 2017
A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing guanylyl cyclase CKhaldoun Almhanna, David Wright, Teresa Macarulla Mercade, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 13, 2022
Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 TrialThomas Yau, Vittorina Zagonel, Armando Santoro, et al.Journal of Hepatology|May 29, 2021
CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosisMasatoshi Kudo, Ana Matilla, Armando Santoro, et al.The Oncologist|March 31, 2025
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer: safety analysis of FRESCO-2Cathy Eng, Arvind Dasari, Sara Lonardi, et al.Hepatology (Baltimore, Md.)|March 31, 2023
Phase 2 trial of bintrafusp alfa as second-line therapy for patients with locally advanced/metastatic biliary tract cancersChanghoon Yoo, Milind M Javle, Helena Verdaguer Mata, et al.Pageof 6